Tang Yiyun

Tang Yiyun

Areas of practice

Ms. Tang Yiyun advises international and Chinese corporations as lead advisor on a diverse range of matters including inbound and outbound M&A, strategic alliances, private equity investments and post-merger integrations.

Ms Tang has many years of experience in advising M&A transactions related to port shipping, energy, mining, medical and health care and other industries. Ms. Tang’s representative transactions include: the integration of Liaoning Ports, judicial reorganization of Dandong Port Entities,the capital increase and debt-for-equity exchange of Yingkou Port Group at the value of RMB58.9 billion, CMSI’s participation in the system restructuring of Zhanjiang Port (Group) Co., Ltd., China. Shipping Terminal Development Co., Ltd.’s acquisition of a Belgian port company, and acquisitions of oil blocks in central Asia and investment projects in South America, Australia and Russia by several energy and mineral resources investment companies, and domestic and overseas investment transactions by Sinopharm Group Co., Ltd.

With over ten years of experience in various types of cross-border investments (representing both sellers and buyers), Ms. Tang serves clients in the increasingly active outbound and inbound M&A practice (in particular outbound investments in the U.K., Continental Europe and Asia), effectively coordinates and implements comprehensive offshore due diligence, structuring, documentation, regulatory approval procedures and closing, and bridges the communications among clients, offshore targets and sellers, local legal teams and other involved advisors. Representative transactions she advised on include Ping An Overseas Holdings’ sale of Yi Hao Dian to Wal-mart Stores, Inc. and the acquisition of Fullerton Capital International from Temasek Holdings, Shanghai Jin Jiang International Hotels Development Co., Ltd.’s US$1.3 billion acquisition of Plateno Group (including 7 Days Inn and other overseas and domestic brand hotels), Ajinomoto Co., Inc.’s acquisition of Shanghai Amoy Food Co. Ltd., Volvo’s acquisition of a Chinese motor company and others.

In the field of investment by both domestic and overseas private equity funds, Ms.Tang has advised a great number of private equity funds, venture capital institutions and investee companies on transactions such as the $485 million Series A financing of Shanghai Lujiazui International Financial Asset Exchange Co., Ltd., Series B financing of Eddingpharm by OrbiMed Asia, Domain Partners and Sequoia Capital, as well as establishment of an M&A fund in Europe.

Ms. Tang has a wealth of experience advising insurers and financial institutions on cross-border M&A, compliance, corporate governance, onshore and offshore investments using insurance fund. The representative transactions include Carlyle Asia’s US$400 million investment in China Pacific Life, Carlyle Asia and Dah Sing Bank’s RMB1 billion joint investment in Chongqing Commercial Bank, Fosun International Limited’s overseas acquisition of insurance companies and financial institutions, the formation of Sino-foreign JV life insurance company by New York Life Insurance Company and Qingdao Haier Investment and Development Company,  Citibank’s strategic cooperation with Shanghai Pudong Development Bank. Ms. Tang also advises insurance asset management companies on investments using insurance fund, reviews and advises on insurance policies and compliance matters. 

Ms. Tang also has substantial sector experience in M&A involving infrastructure, energy, mineral and health among other industries. She advised on China Merchants Holdings (International) Co., Ltd.’s investment in Zhanjiang Port Group Co., Ltd., China Shipping Terminal Developments’ acquisition of a Belgian port company, several energy and mineral investment companies on acquisitions of oil fields in Central Asia, investments in mining projects in South America, Australia and Russia, domestic and overseas investments of Sinopharm Group Co. Ltd. and others.

In addition, in the field of investment in domestic and foreign private equity funds, Ms. Tang provided legal services to a number of domestic and foreign private equity firms, venture capital firms and target companies, including Shanghai Lujiazui International Financial Asset Exchange Co.’s US$ 485 million series A investment, OrbiMed Asia, Domain Partners and Sequoia’ series B investment in Eddingpharm group, the formation of M&A fund in Europe and others.

Over the years, Ms. Tang has not only devoted herself to her legal practice, but has also been invited as keynote speaker in a range of activities such as forums, lectures, training and workshops on M&A and restructuring as well as compliance of state-owned enterprises. Ms. Tang has also actively participated in the professional activities organized by new and existing clients and related organizations, including local Association of Corporate Counsel. She is regarded as a trusted advisor, reputation from a wide range of clients.

Work experience

Ms. Tang rejoined King & Wood Mallesons in 2017. Ms. Tang practiced at King & Wood Mallesons from 2002 to 2005. She then served at Linklaters, Morrison & Foerster and DLA Piper from 2005 to 2017. She was in-house counsel at the Shanghai Branch of Tokyo Marine and Fire Insurance Company Limited.

Ms. Tang received her LL.B. from East China University of Political Science and Law in 2001.

She is qualified to practice law in China, and is a solicitor of the Senior Courts of England and Wales.

Her working languages are Chinese and English. She is also proficient in communicating in Japanese.


Legal insights

The swap takes the form of acquisition, where Liaoning Port Group and bank creditors subscribed for new registered capital of Yingkou Port Group with cash, relevant equities and debt claims ...

16 January 2019

the participants of the transaction worked together to successfully close the Liaoning Port Group acquisition transaction on 3 December 2018.

16 January 2019

This site uses cookies to enhance your experience and to help us improve the site. Please see our Privacy Policy for further information. If you continue without changing your settings, we will assume that you are happy to receive these cookies. You can change your cookie settings at any time.

For more information on which cookies we use then please refer to our Cookie Policy.